Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
NCT01721291
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsNCT Number: NCT04928417
Observational, cross-sectional study with retrospective data collection from medical records. During the cross-sectional study visit, data will be captured through the use of electronic Case Report Forms (eCRFs). As there will be only one study visit, no prospective data collection will take place, nor collection of data that are not part of the routine clinic visit.
For understanding the burden of severe exacerbations of COPD and the association between frequency of severe exacerbations and clinical and health-care utilization outcomes in less well-resourced countries
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Research Site, Santiago, Chile
Observational, cross-sectional study with retrospective data collection from medical records. During the cross-sectional study visit, data will be captured through the use of electronic Case Report Forms (eCRFs). As there will be only one study visit, no prospective data collection will take place, nor collection of data that are not part of the routine clinic visit.
For understanding the burden of severe exacerbations of COPD and the association between frequency of severe exacerbations and clinical and health-care utilization outcomes in less well-resourced countries
Patients, treated by pulmonologists, with an investigator-confirmed diagnosis of COPD for at least 5 years from the index date (the date that signed Informed Consent was obtained) and who meet all of the inclusion and none of the exclusion criteria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 YEAR
Number of severe Acute exacerbation of COPD events and interval between severe AECOPDs over the past 5 years
Time frame: 5 YEAR
At least 2 (Forced expiratory volume in 1 second)FEV1 measurements at least 6 months apart
Time frame: 5 YEARS
Number of hospitalizations due to AECOPD in 60 months prior to study visit and time between hospitalizations
Time frame: 1 YEAR
Modified Medical Research Council (mMRC) dyspnea questionnaire to asses the grade as follow:
AstraZeneca
Industry
Exacerbations and Their Outcomes International (EXACOS International): Understanding Burden of Severe Exacerbations of COPD and Association Between Frequency of Severe Exacerbations Clinical and Health-care Utilization Outcomes in Less Well-resourced Countries
Acronym: EXACOS-Intl
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01721291
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsNCT05326412
Chronic Disease, Chronic Obstructive Pulmonary Disease
Torrance, California, United States
View Trial DetailsNCT07016412
Chronic Disease, Chronic Obstructive Pulmonary Disease
Dothan, Alabama, United States
View Trial DetailsNCT05641207
Bronchial Diseases, Bronchitis
Beijing, Beijing Municipality, China
View Trial Details